With Eli Lilly & Co. sealing the deal to acquire its partner Loxo Oncology Inc., Bayer AG has moved swiftly to take full control of its tissue-agnostic drug Vitrakvi rather than share the rights to the closely watched cancer therapy with a fellow big pharma.
Bayer Bags Full Vitrakvi Rights As Lilly Signs Off Loxo Buy
When buying Loxo, Lilly highlighted the importance of LOXO-292, a first-in-class oral RET inhibitor, rather than the already-approved Vitrakvi, perhaps knowing that partner Bayer was going to be exercising an option to take full control of the TRK inhibitor.
More from Deals
• By
Chinese biopharma companies’ alliance strategies are transitioning from immediate cash needs to more strategic management of portfolios, as MNCs continue to hunt for derisked assets.
• By
The biotech has rejected a takeover bid from Nordic Capital but a sale to private equity could be a solution to the public market's continued reluctance to adequately value PureTech’s hub-and-spoke business model.
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.
More from Business
• By
There were six biopharma initial public offerings on Western stock exchanges, including five in the US, during the first quarter, but plunging stock values could halt further IPOs.
• By
Sector-specific tariffs, including on pharmaceuticals, could be announced as early as this week.
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.